Guidance
Evidence-based recommendations on the ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury.
Implementation
NICE has developed tools, in association with relevant stakeholders, to help organisations put this guidance into practice.
Is this guidance up to date?
We reviewed the evidence in August 2020. We found nothing new that affects the recommendations in this guidance.
Since October 2018 ReCell has not been actively marketed to new NHS users and the sale of ReCell in the UK is currently still limited to existing users.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
Guidance development process
How we develop NICE medical technologies guidance
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.